Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX.
Dermatol Online J. 2020 Sep 15;26(9):13030/qt01q4m0p0.
Cutaneous non-tuberculous mycobacterial (NTM) infections have rapidly increased in incidence in recent years. Currently there is no standard treatment and the variable and nonspecific ways in which cutaneous NTM infection presents makes it a therapeutic and diagnostic challenge. We describe a 67-year-old immunocompetent woman with cutaneous NTM infection after she recently underwent a root canal procedure. Although the species was not identified and she was unable to tolerate multiple antibiotics, she ultimately responded well to three months of treatment with linezolid. Given that cutaneous NTM infection can present in immunocompetent patients and that the incidence is rising, it is important for clinicians to maintain a high index of clinical suspicion, especially in patients with a recent history of surgery, trauma, or cosmetic procedures. Linezolid has coverage against non-tuberculous mycobacteria and is an effective therapeutic option for cutaneous NTM cases in which identification to the species level is not possible or when adverse effects limit therapeutic options.
近年来，皮肤非结核分枝杆菌（NTM）感染的发病率迅速上升。目前尚无标准治疗方法，而且皮肤 NTM 感染的表现方式多样且不具特异性，这使其成为治疗和诊断的挑战。我们描述了一位 67 岁免疫功能正常的女性，她在最近接受根管治疗后发生了皮肤 NTM 感染。尽管未鉴定出菌种，且她无法耐受多种抗生素，但她最终对三个月的利奈唑胺治疗反应良好。鉴于皮肤 NTM 感染可发生于免疫功能正常的患者，且发病率正在上升，临床医生保持高度的临床怀疑指数非常重要，特别是对于近期有手术、创伤或美容手术史的患者。利奈唑胺对非结核分枝杆菌具有覆盖作用，是无法确定菌种水平或不良反应限制治疗选择时，治疗皮肤 NTM 病例的有效治疗选择。
